Entities / Company
Bio-Techne.
company
- Reports this week
- 0
- Active events
- 0
- Connections
- 82
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
-
Bio-Techne shares traded on Nasdaq, and TD Cowen reiterated a Buy rating with a $65 price target.Well supported6 reports
-
Bio-Techne has entered a strategic partnership with Spear Bio to distribute its immunoassays, advancing therapeutic development.Some support2 reports
-
Trump pledged to unleash American oil and gas, involving MBX Biosciences, Inc.Some support5 reports
-
Merck KGaA announced a definitive agreement to acquire Bio-Techne.Well supported6 reports
-
Bio-Techne operates in European, US, and Middle Eastern markets and is listed on NASDAQ.Some support1 report
One to three months ago
-
Bio-Techne is facing scrutiny regarding its market performance and the growth of Protein Sciences, questioned by a UBS analyst.Some support1 report2 developments inside
-
Bio-Techne sells products in Africa and the Middle East and operates through its Protein Sciences segment.Some support2 reports
-
Bio-Techne, Sartorius, Thermo Fisher, and Danaher are noted as leading peers in the life science tools industry.Some support1 report1 development inside
-
Bio-Techne listed its shares on the NASDAQ stock exchange on August 1, 2026.Well supported10 reports
-
Norges Bank acquired a new stake in Bio-Techne, and the company filed the required reports with the SEC on July 27, 2026.Some support1 report
Gone quiet
No new reports in 90+ days-
Bio-Techne is headquartered in Minneapolis.Well supported6 reports
-
Merck KGaA agreed to acquire Bio-Techne, while an analyst boosted the price target for Avantor stock.Some support1 report
-
Bio-Techne traded on the Nasdaq.Well supported3 reports
-
Bio-Techne and Thermo Fisher Scientific Inc. are being monitored for peer company performance comparison in the market.Some support1 report
-
Citigroup and RBC issued rating updates and price targets for Bio-Techne on June 6, 2026, which is listed on the Nasdaq stock exchange.Some support3 reports
-
Kadant, Bio-Techne, Nike, and Abbott Laboratories were noted on July 3, 2025, as high-quality, large-cap companies included in the S&P 500.Speculative1 report
-
Trump clarified that tariffs could rise if a full deal is not reached, coinciding with analyst coverage initiated on Bio-Techne.Some support1 report
-
Tariff policies caused market volatility, and favorable Fed signals drove U.S. equities rise, impacting CoStar Group.Some support3 reports1 development inside
-
Bio-Techne sold USP reference standards and accelerated product development in collaboration with U.S. Pharmacopeia.Speculative2 reports
-
Bio-Techne utilized the Maurice system for analytical solutions.Speculative1 report
-
Bio-Techne is facing market scrutiny as various analysts, including those from UBS and William Blair, inquire about academic headwinds and growth clarity.Speculative1 report
-
NIH funding uncertainty affects Bio-Techne guidance.Some support2 reports1 development inside
-
Headwaters Capital Management highlighted Bio-Techne in its investor letter.Some support1 report
-
Bio-Techne utilizes LinkedIn and Twitter for social media, with David Clair serving as VP of Investor Relations.Some support1 report
-
Protein Sciences accounts for 72% of net sales for Bio-Techne.Some support2 reports1 development inside
-
The business unit of Protein Sciences is generating cash flows.Some support1 report
-
TD Cowen analysts initiated a new Buy rating for Bio-Techne on July 28, 2025.Some support1 report
-
Aristotle Atlantic highlighted Bio-Techne in its investor letter, preferring certain AI stocks over the company.Some support1 report
-
Bio-Techne and Bloomin' Brands experienced stock price declines on August 7, 2025.Some support1 report
-
Bio-Techne, West Pharmaceutical Services, and BioMarin Pharmaceutical operate within the pharmaceutical supply chain, with WST providing packaging for injectable drugs.Some support1 report
-
Bessent's call on August 14, 2025, regarding rate cuts benefiting growth sectors, specifically mentioning UFP Technologies and Bio-Techne.Some support1 report
-
A tariff plan caused market tanking, impacting companies Zscaler and Bio-Techne.Some support1 report
-
KTVQ, Masimo, and Bio-Techne were featured in Wall Street analysis as investment opportunities on September 2, 2025.Some support2 reports
-
Bio-Techne was affected by the easing of market concerns following Jerome Powell's dovish remarks on September 3, 2025.Some support1 report
-
Bio-Techne and Myriad Genetics are identified as key players in the biomarkers industry, while the American Cancer Society provides prostate cancer prevalence statistics.Some support1 report
-
Bio-Techne, ICF International, and Kadant were mentioned as small-cap stocks analyzed by StockStory on September 5, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Bio-Techne this week
News at the entities that move Bio-Techne most-
Merck KGaA TransactionalNasdaq added Moderna to its Nasdaq-100 index, and Moderna combined its vaccine with Merck's drug.Moves Bio-Techne
-
SEC StructuralLedjr AI acquired voting control of SPYR, which must now file a registration statement with the SEC and aims for a Nasdaq listing.Moves Bio-Techne
-
William P. Blair OperationalJefferies Financial Group initiated coverage of Suja Life, Inc., providing a buy rating and price objective as of July 18, 2026.Moves Bio-Techne
-
Stephens Mentioned togetherSeveral financial firms, including SummerHaven and Diversify Wealth Management, acquired new stakes in DXP Enterprises.Moves Bio-Techne
-
Invesco StructuralInvesco sponsors the Invesco Dorsey Wright Technology Momentum ETF, which was established on August 13, 2025.Moves Bio-Techne
-
TD Cowen Mentioned togetherSean O’Loughlin reiterated a Buy rating on Coherent, supported by TD Cowen analysts.Moves Bio-Techne
Connections
The 25 strongest of 82, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Merck KGaA Transactional
Merck KGaA is acquiring Bio-Techne through a definitive shareholder sale agreement.
-
Nasdaq Structural
Bio-Techne is formally listed and trades as a company on the Nasdaq stock exchange.
-
Protein Sciences Structural
Protein Sciences functions as a major segment of Bio-Techne, accounting for 72% of its net sales.
-
SEC Structural
Bio-Techne operates under the mandatory regulatory oversight of the U.S. Securities and Exchange Commission (SEC).
-
Thermo Fisher Scientific Inc. Operational
The two companies are actively engaged in competition within the market through peer performance comparisons.
-
Norges Bank Transactional
Norges Bank acquired a new investment stake in Bio-Techne stock.
-
Invesco Structural
Invesco ETF holds Bio-Techne as a top position, establishing a financial investment link.
-
William P. Blair Operational
William Blair has actively influenced Bio-Techne's stock rating and market perception through investment analysis.
Show all 25 connections
-
BioNano Genomics Operational
Bio-Techne and BioNano Genomics are actively competing within the life science and biotech market.
-
Stephens Mentioned together
Stephens provided financial analysis, setting a target price, for Bio-Techne.
-
MarketBeat Mentioned together
MarketBeat reports and tracks Bio-Techne's stock and company performance.
-
Champions Oncology Operational
Champions Oncology and Bio-Techne are identified as competitors within the life science market.
-
TD Cowen Mentioned together
TD Cowen provides financial analyst ratings and coverage for Bio-Techne.
-
University of Minnesota Structural
University researchers utilize products supplied by Bio-Techne for their research activities.
-
Boca Raton Shared context
The company Bio-Techne operates in the context of international business operations.
-
Benchmark Transactional
Benchmark issued and restated stock ratings regarding Bio-Techne.
-
Leerink partners Mentioned together
Leerink partners provides financial price targets and analysis for Bio-Techne.
-
Europe Shared context
Bio-Techne conducts business operations within the geographical and economic context of Europe.
-
Royal Bank of Canada Mentioned together
RBC issued an outperform rating and price objective for Bio-Techne.
-
SPX Mentioned together
Bio-Techne's stock performance is tracked relative to the SPX market index.
-
Citigroup Mentioned together
Citigroup provided market analysis on Bio-Techne, including a price objective reduction and a buy rating.
-
Minnesota Shared context
Bio-Techne is headquartered and operates as a company within the state of Minnesota.
-
Africa Shared context
Bio-Techne operates and sells products within the African market.
-
Middle East Shared context
Bio-Techne operates and sells products within the Middle East markets.
-
Minneapolis Shared context
Bio-Techne maintains its corporate headquarters and operational base within the city of Minneapolis.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
1 eventJuly 2026
1 eventShow 1 earlier month
June 2026
32 events- Bio-Techne shares traded on Nasdaq, and TD Cowen reiterated a Buy rating with a $65 price target.
- Bio-Techne has entered a strategic partnership with Spear Bio to distribute its immunoassays, advancing therapeutic development.
- Trump pledged to unleash American oil and gas, involving MBX Biosciences, Inc.
- Merck KGaA announced a definitive agreement to acquire Bio-Techne.
- Bio-Techne is facing scrutiny regarding its market performance and the growth of Protein Sciences, questioned by a UBS analyst.
- Bio-Techne, Sartorius, Thermo Fisher, and Danaher are noted as leading peers in the life science tools industry.
- Bio-Techne is headquartered in Minneapolis.
- Merck KGaA agreed to acquire Bio-Techne, while an analyst boosted the price target for Avantor stock.
- Bio-Techne traded on the Nasdaq.
- Bio-Techne and Thermo Fisher Scientific Inc. are being monitored for peer company performance comparison in the market.
- Citigroup and RBC issued rating updates and price targets for Bio-Techne on June 6, 2026, which is listed on the Nasdaq stock exchange.
- Kadant, Bio-Techne, Nike, and Abbott Laboratories were noted on July 3, 2025, as high-quality, large-cap companies included in the S&P 500.
- Trump clarified that tariffs could rise if a full deal is not reached, coinciding with analyst coverage initiated on Bio-Techne.
- Tariff policies caused market volatility, and favorable Fed signals drove U.S. equities rise, impacting CoStar Group.
- Bio-Techne sold USP reference standards and accelerated product development in collaboration with U.S. Pharmacopeia.
- Bio-Techne utilized the Maurice system for analytical solutions.
- Bio-Techne is facing market scrutiny as various analysts, including those from UBS and William Blair, inquire about academic headwinds and growth clarity.
- NIH funding uncertainty affects Bio-Techne guidance.
- Headwaters Capital Management highlighted Bio-Techne in its investor letter.
- Bio-Techne utilizes LinkedIn and Twitter for social media, with David Clair serving as VP of Investor Relations.
- Protein Sciences accounts for 72% of net sales for Bio-Techne.
- The business unit of Protein Sciences is generating cash flows.
- TD Cowen analysts initiated a new Buy rating for Bio-Techne on July 28, 2025.
- Aristotle Atlantic highlighted Bio-Techne in its investor letter, preferring certain AI stocks over the company.
- Bio-Techne and Bloomin' Brands experienced stock price declines on August 7, 2025.
- Bio-Techne, West Pharmaceutical Services, and BioMarin Pharmaceutical operate within the pharmaceutical supply chain, with WST providing packaging for injectable drugs.
- Bessent's call on August 14, 2025, regarding rate cuts benefiting growth sectors, specifically mentioning UFP Technologies and Bio-Techne.
- A tariff plan caused market tanking, impacting companies Zscaler and Bio-Techne.
- KTVQ, Masimo, and Bio-Techne were featured in Wall Street analysis as investment opportunities on September 2, 2025.
- Bio-Techne was affected by the easing of market concerns following Jerome Powell's dovish remarks on September 3, 2025.
- Bio-Techne and Myriad Genetics are identified as key players in the biomarkers industry, while the American Cancer Society provides prostate cancer prevalence statistics.
- Bio-Techne, ICF International, and Kadant were mentioned as small-cap stocks analyzed by StockStory on September 5, 2025.